Drugs / Agrippal®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01879553 | Jul → Aug 2013 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Agrippal | “A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine...” NCT01879553 ↗ |
| Known as | TIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01879553 ↗ |
| Modality | Vaccine | “Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)” NCT01879553 ↗ |